Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Muscle Nerve. 2018 Dec 26;59(3):303–308. doi: 10.1002/mus.26385

Table 2.

Disease progression (expressed as change per month) at Week 23.

Outcome of disease progression All Participants
(N=16)
ALSFRS-R Total Score
Mean ± SD (Min-Max)		 −1.1 ± 1.72†
(−2.3, −0.2)
SVC
Mean ± SD (Min-Max)		 −0.6 ± 4.41
(−4.9, 1.9)
ATLIS Arm Measures (%)
Mean ± SD (Min-Max)		 −1.7 ± 3.12†
(−4.2, 0)
ATLIS Leg Measures (%)
Mean ± SD (Min-Max)		 −1.7 ± 5.61†
(−8, 1)

Data are presented as means (±SD) (expressed as change per month). Minimum and maximum changes are shown in parenthesis.

Abbreviations: ALSFRS-R= ALS functional rating scale revised. ATLIS: Accurate Test of Limb Isometric Strength (results are presented as percent of predicted values)32. N= number of subjects. SD=standard deviation. SVC= slow vital capacity (results are presented as percent of predicted values for age, gender and height).

†

Denotes statistically significant Wilcoxon for change at Week 23 compared to Baseline (p < 0.05).